Page last updated: 2024-11-04

vorinostat and Acute Lymphoid Leukemia

vorinostat has been researched along with Acute Lymphoid Leukemia in 8 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure."1.36Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. ( Barredo, JC; Leclerc, GJ; Leclerc, GM; Mian, AM; Mou, C, 2010)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Yoshida, K1
Fujita, A1
Narazaki, H1
Asano, T1
Itoh, Y1
Shirazi, PT1
Eadie, LN1
Heatley, SL1
Page, EC1
François, M1
Hughes, TP1
Yeung, D1
White, DL1
Rivera-Del Valle, N1
Cheng, T1
Irwin, ME1
Donnella, H1
Singh, MM1
Chandra, J1
Kuang, SQ1
Fang, Z1
Zweidler-McKay, PA1
Yang, H1
Wei, Y1
Gonzalez-Cervantes, EA1
Boumber, Y1
Garcia-Manero, G1
Burke, MJ1
Lamba, JK1
Pounds, S1
Cao, X1
Ghodke-Puranik, Y1
Lindgren, BR1
Weigel, BJ1
Verneris, MR1
Miller, JS1
Leclerc, GJ1
Mou, C1
Leclerc, GM1
Mian, AM1
Barredo, JC1
Okabe, S1
Tauchi, T1
Ohyashiki, K1
Bachmann, PS1
Piazza, RG1
Janes, ME1
Wong, NC1
Davies, C1
Mogavero, A1
Bhadri, VA1
Szymanska, B1
Geninson, G1
Magistroni, V1
Cazzaniga, G1
Biondi, A1
Miranda-Saavedra, D1
Göttgens, B1
Saffery, R1
Craig, JM1
Marshall, GM1
Gambacorti-Passerini, C1
Pimanda, JE1
Lock, RB1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)[NCT00882206]Phase 215 participants (Actual)Interventional2009-04-30Terminated (stopped due to Slow accrual)
A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia[NCT00500006]Phase 13 participants (Actual)Interventional2007-10-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Level of Methylation

the percentage of methylated DNA (NCT00882206)
Timeframe: Day 0

Interventionpercentage of DNA (Mean)
Decitabine / Vorinostat84.98

Level of Methylation

the percentage of methylated DNA (NCT00882206)
Timeframe: Day 33

Interventionpercentage of DNA (Mean)
Decitabine / Vorinostat86.1

Level of Methylation

the percentage of methylated DNA (NCT00882206)
Timeframe: Day 5

Interventionpercentage of DNA (Mean)
Decitabine / Vorinostat79.82

Response to Treatment

Response includes both complete remission (defined as <5% leukemic blasts in the bone marrow) and partial remission (defined as a greater than 35% reduction in the bone marrow leukemia blast percentage at day 33) (NCT00882206)
Timeframe: Day 33

Interventionparticipants (Number)
Decitabine / Vorinostat6

Trials

1 trial available for vorinostat and Acute Lymphoid Leukemia

ArticleYear
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
    American journal of hematology, 2014, Volume: 89, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Presch

2014

Other Studies

7 other studies available for vorinostat and Acute Lymphoid Leukemia

ArticleYear
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:1

    Topics: Acetylation; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; CpG Islands; Deoxycytidine

2022
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.
    Cancer gene therapy, 2022, Volume: 29, Issue:8-9

    Topics: Animals; Janus Kinase Inhibitors; Mice; Oncogenes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; S

2022
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:3

    Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; DNA Fragmentation; Drug

2018
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Apoptosis; Azacitidine; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Blood Cells; Bo

2013
Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
    Leukemia, 2010, Volume: 24, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Binding Factor; Cell Line, Tumor; Exons; Gene

2010
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
    Annals of hematology, 2010, Volume: 89, Issue:11

    Topics: Adult; Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Co

2010
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Blood, 2010, Oct-21, Volume: 116, Issue:16

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Bcl-

2010